Vertex Pharmaceuticals (NASDAQ:VRTX) has posted new data from a Phase 1/2/3 study for zimislecel (VX-880), its experimental ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 10 biotech stocks screaming a buy. On June 17, RBC Capital ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data ...

In the latest close session, Vertex Pharmaceuticals (VRTX) was down 1.68% at $440.87. The stock fell short of the S&P 500, which registered a loss of 0.22% for the day. Meanwhile, the Dow gained 0.08% ...

Vertex Pharmaceuticals Inc. closed 15.20% short of its 52-week high of $519.88, which the company achieved on November 8th.

Shares of Vertex Pharmaceuticals Inc. VRTX rose 1.45% to $448.40 Wednesday, on what proved to be an all-around rough trading ...

Vertex Pharmaceuticals is laying off workers and consolidating its real estate footprint in Rhode Island after ending a ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $482.4, with a high estimate of $567.00 and a low estimate of $420.00. This current average ...

The layoffs will be effective on Aug. 5, according to a letter sent to the state’s Department of Labor and Training.

The leading Cystic Fibrosis Companies such as Verona Pharma, Armata Pharmaceuticals, 4D Molecular Therapeutics, Spirovant ...